Enrollment is closed for CLL, FL grade 1-3a and aggressive lymphoma cohorts. The only
        cohort that remains open for enrollment is the DLBCL after failure of CAR-T therapy cohort.

        Key Inclusion Criteria:

          1. Have documented CD20+ B-cell malignancy, with active disease not responsive to prior
             therapy, for whom no standard of care options exists, and for whom treatment with an
             anti-CD20 antibody may be appropriate.

          2. Patients with NHL must have had prior treatment with an anti-CD20 antibody therapy.
             Patients with CLL are not required to have received prior treatment with an anti-CD20
             antibody therapy, provided the patient has failed either a BTK inhibitor or PI3K
             inhibitor and the treating physician deems it appropriate for the patient to be
             entered into a phase 1 trial.

               -  For inclusion in the FL grade 1-3a expansion cohort, patients must have received
                  at least 2 prior lines of systemic therapy, including an anti-CD20 antibody and
                  an alkylating agent.

               -  For the inclusion in the disease-specific expansion cohort enrolling DLBCL
                  patients after failure of CAR-T therapy, the patient must have recovered from the
                  toxicities of the lymphodepletion therapy and CAR-T infusion.

          3. Must have at least one bi-dimensionally measurable lesion ≥1.5 cm on the longest
             diameter documented by CT or MRI scan.

          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤1

          5. Life expectancy of at least 6 months

          6. Adequate bone marrow function documented by:

               1. Platelet counts ≥75 x 10^9/L

               2. Hb level ≥9 g/dL

               3. Absolute neutrophil count (ANC) ≥1 x 10^9/L

          7. Adequate organ function documented by:

               1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 X ULN

               2. Total bilirubin ≤1.5 X ULN

               3. Calculated creatinine clearance by Cockcroft-Gault ≥50 mL/min (patients with
                  borderline creatinine clearance by Cockcroft-Gault may be considered for
                  enrollment if a measured creatinine clearance (based on 24-hour urine or other
                  reliable method) is ≥50 mL/min)

          8. Willing and able to comply with clinic visits and study-related procedures

          9. Provide signed informed consent

        Key Exclusion Criteria:

          1. Primary central nervous system (CNS) lymphoma or known or suspected CNS involvement by
             non-primary CNS NHL

          2. History of or current relevant CNS pathology

          3. Allogeneic stem cell transplantation

          4. Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis
             B virus (HBV) or hepatitis C virus (HCV). Patients with hepatitis B (HepBsAg+) who
             have controlled infection (serum hepatitis B virus DNA that is below the limit of
             detection AND receiving anti-viral therapy for hepatitis B) are permitted upon
             consultation with the physician managing the infection.

          5. Known hypersensitivity to both allopurinol and rasburicase

          6. History of hypersensitivity to any compound in the tetracycline antibiotics group

        The information provided above is not intended to contain all considerations relevant to
        potential participation in a clinical trial therefore not all inclusion/ exclusion criteria
        are listed.